

## Special Issue

# Recent Progress on Vaccine Development against Infectious Diseases

### Message from the Guest Editors

Vaccination is one of the most effective measures to prevent the spreading of infectious diseases, including the ongoing catastrophic coronavirus disease 2019 (COVID-19) pandemic. Thanks to the worldwide resource and endeavor, two mRNA-based vaccines, which are the first of the class, are available within one year since the discovery of the causative agent. However, the field still faces big challenges ahead. This special issue focuses on the most recent progress and current vaccine development in the vaccine. We sincerely invite you to contribute an original research article, review, or perspective on the latest researches to highlight, (i) novel experimental vaccine candidates, (ii) novel adjuvants and delivery vehicles, (iii) immune responses elicited by a novel vaccine, (iv) concerns and optimizations of vaccine strategies. This special issue emphasizes on major infectious diseases caused by viruses, but related topics on other human pathogens, such as bacteria, fungi, and parasites, are also welcomed.

### Guest Editors

Dr. Xiaohua Ye

Dr. Zhiqiang Ku

Dr. Srinivasa Reddy Bonam

### Deadline for manuscript submissions

closed (15 June 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/105730](https://mdpi.com/si/105730)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).